Switch theme
Sign up to access all valuation multiples
Shenzhen New Industries Biomedical Engineering Co Ltd is researching, developing, producing and selling a series of fully automatic chemiluminescence immunoassay instruments and supporting reagents.
1995
n/a
LTM Revenue $666M
LTM EBITDA $321M
$6.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Snibe has a last 12-month revenue (LTM) of $666M and a last 12-month EBITDA of $321M.
In the most recent fiscal year, Snibe achieved revenue of $629M and an EBITDA of $316M.
Snibe expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Snibe valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $666M | XXX | $629M | XXX | XXX | XXX |
| Gross Profit | $477M | XXX | $454M | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 72% | XXX | XXX | XXX |
| EBITDA | $321M | XXX | $316M | XXX | XXX | XXX |
| EBITDA Margin | 48% | XXX | 50% | XXX | XXX | XXX |
| EBIT | $301M | XXX | $276M | XXX | XXX | XXX |
| EBIT Margin | 45% | XXX | 44% | XXX | XXX | XXX |
| Net Profit | $266M | XXX | $254M | XXX | XXX | XXX |
| Net Margin | 40% | XXX | 40% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Snibe's stock price is CNY 60 (or $8).
Snibe has current market cap of CNY 47.1B (or $6.5B), and EV of CNY 44.7B (or $6.2B).
See Snibe trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.2B | $6.5B | XXX | XXX | XXX | XXX | $0.34 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Snibe has market cap of $6.5B and EV of $6.2B.
Snibe's trades at 9.8x EV/Revenue multiple, and 19.6x EV/EBITDA.
Equity research analysts estimate Snibe's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Snibe has a P/E ratio of 24.6x.
See valuation multiples for Snibe and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.5B | XXX | $6.5B | XXX | XXX | XXX |
| EV (current) | $6.2B | XXX | $6.2B | XXX | XXX | XXX |
| EV/Revenue | 9.3x | XXX | 9.8x | XXX | XXX | XXX |
| EV/EBITDA | 19.3x | XXX | 19.6x | XXX | XXX | XXX |
| EV/EBIT | 20.6x | XXX | 22.5x | XXX | XXX | XXX |
| EV/Gross Profit | 13.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 24.6x | XXX | 25.8x | XXX | XXX | XXX |
| EV/FCF | 38.0x | XXX | 48.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSnibe's last 12 month revenue growth is 15%
Snibe's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Snibe's rule of 40 is 68% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Snibe's rule of X is 87% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Snibe and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 48% | XXX | 50% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 10% | XXX | XXX | XXX |
| Rule of 40 | 68% | XXX | 66% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 87% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Snibe acquired XXX companies to date.
Last acquisition by Snibe was XXXXXXXX, XXXXX XXXXX XXXXXX . Snibe acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Snibe founded? | Snibe was founded in 1995. |
| Where is Snibe headquartered? | Snibe is headquartered in China. |
| Is Snibe publicy listed? | Yes, Snibe is a public company listed on SHE. |
| What is the stock symbol of Snibe? | Snibe trades under 300832 ticker. |
| When did Snibe go public? | Snibe went public in 2020. |
| Who are competitors of Snibe? | Similar companies to Snibe include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Snibe? | Snibe's current market cap is $6.5B |
| What is the current revenue of Snibe? | Snibe's last 12 months revenue is $666M. |
| What is the current revenue growth of Snibe? | Snibe revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Snibe? | Current revenue multiple of Snibe is 9.3x. |
| Is Snibe profitable? | Yes, Snibe is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Snibe? | Snibe's last 12 months EBITDA is $321M. |
| What is Snibe's EBITDA margin? | Snibe's last 12 months EBITDA margin is 48%. |
| What is the current EV/EBITDA multiple of Snibe? | Current EBITDA multiple of Snibe is 19.3x. |
| What is the current FCF of Snibe? | Snibe's last 12 months FCF is $163M. |
| What is Snibe's FCF margin? | Snibe's last 12 months FCF margin is 25%. |
| What is the current EV/FCF multiple of Snibe? | Current FCF multiple of Snibe is 38.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
